Lumipulse® G NfL Blood (CE marked (IVDR))
Lumipulse G NfL Blood is a quantitative test for in vitro diagnostic use with the automated LUMIPULSE G System for the measurement of neurofilament light chain (NfL) in human blood (serum/plasma) in patients with neurological diseases.
Lumipulse® G NfL Blood assay (CE marked (IVDR))
Receive your quote directly from the manufacturer.
Lumipulse G NfL Blood is a quantitative test for in vitro diagnostic use with the automated LUMIPULSE G System for the measurement of neurofilament light chain (NfL) in human blood (serum/plasma) in patients with neurological diseases.
The assay is intended to detect NfL as a biomarker of neuro-axonal damage irrespective of the cause and can contribute to the monitoring of disease activity.
This biomarker should be evaluated in combination with clinical investigations and other disease characteristics. This product is for professional use only.
CE marked (IVDR)
Please contact your local Fujirebio representative for the availability of this product in your country.
Expanding access to Alzheimer’s biomarker testing
Early diagnosis can make a meaningful difference for patients and families affected by Alzheimer’s disease and other neurological conditions. In this Fujirebio video, discover how decades of diagnostic innovation, investment in neurodiagnostics, and the work of the Fujirebio Neuro Center of Excellence are helping advance reliable biomarker testing.
Plus, explore Fujirebio’s open partnership model, which is designed to share innovations across platforms and broaden access to advanced assays for laboratories, physicians, and patients worldwide.
How pTau 217 and NfL blood-based biomarkers are reshaping diagnosis in Alzheimer’s and neurodegenerative disease
See why accessible, pathology-informed testing is becoming increasingly important for earlier diagnosis, patient stratification, and more efficient neurological care
